{"entity":{"id":"catenabio","kind":"company","name":"CatenaBio","aka":["Catena Biosciences","Catena Biosciences, Inc."],"tldr":"CatenaBio is a California company that joins two different cancer-killing drugs onto one antibody, so a single medicine can attack a tumour in two ways. Its lead medicine, CATB-101, targets TROP2 and is in laboratory and animal testing.","summary":"CatenaBio (Catena Biosciences) develops multi-payload antibody-drug conjugates with its CysTyr conjugation platform, which links proteins to payloads through cysteine and tyrosine; its science was invented in the laboratories of Jennifer Doudna and Matt Francis at UC Berkeley, and Marco Lobba is chief executive and co-founder. Its pipeline focuses on dual-payload conjugates for solid tumours, led by CATB-101, which targets TROP2; its NCI award funds HER2-targeted multi-payload conjugates. In fiscal year 2026 NCI awarded it USD 1,072,102 under SBIR award 1R44CA314761-01 for site-selective multi-payload HER2-targeted conjugates in breast and gastric cancers.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://catenabio.com/"},{"label":"CatenaBio: pipeline","url":"https://catenabio.com/pipeline/"},{"label":"NIH RePORTER: SBIR award 1R44CA314761-01","url":"https://reporter.nih.gov/project-details/11408201"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc","dual-payload-adc"],"targets":["trop2","her2"],"drugs":["catb-101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["CATB-101 is named in the existing record catb-101 (AACR 2026 abstract), not on the company's pipeline page, which shows the programmes as an image. Read on catenabio.com and NIH RePORTER on 4 November 2026."],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"hq":"El Cerrito, CA","country":"US","companyType":"biotech","website":"https://catenabio.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":1072102,"source":"https://reporter.nih.gov/project-details/11408201","note":"NCI SBIR award (R44) 1R44CA314761-01: Advancing Site-Selective Multi-Payload HER2-Targeted Conjugates to Overcome Resistance and Boost Survival in Breast and Gastric Cancers"}]},"route":"/companies/catenabio/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"catb-101","kind":"drug","name":"CATB-101","route":"/drugs/catb-101/"}]}}